MIZAR THERAPEUTICS INC. — National Aeronautics and Space Administration SBIR Phase II: SBIR PHASE II - MIZAR S/TAR HIGH-THROUGHPUT PLATFORM FOR IDENTIFICATION OF SENESCENCE ALTE
MIZAR THERAPEUTICS INC. — SBIR Phase II award from National Aeronautics and Space Administration.
Phase II SBIR prototype / development signal
- Phase II is where National Aeronautics and Space Administration funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $899,995 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Mizar Therapeutics Inc. was awarded nearly $900,000 by NASA for Phase II SBIR work on a high-throughput platform called S/TAR. The platform aims to identify drugs that alter cellular senescence to support human health during space missions.
- Amount
- $899,995
- Agency
- National Aeronautics and Space Administration · National Aeronautics and Space Administration
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- MA
- Period
- 2025-09-29 → 2027-09-28
Technology domains
Description
SBIR PHASE II - MIZAR S/TAR HIGH-THROUGHPUT PLATFORM FOR IDENTIFICATION OF SENESCENCE ALTERING THERAPEUTICS